HTB

Hepatitis coinfection

UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’

FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US

FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17

Cochrane review of HCV treatment misses real issues of access to care

Other selections and webcasts

Tenofovir alafenamide (TAF) approved in US to treat hepatitis B with EU set to follow

2016 hepatitis C virus (HCV) update

New HBV drugs and non-viral liver disease in HIV positive people

High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV

NICE approves ombitasvir, paritaprevir, ritonavir with or without dasabuvir to treat adult HCV

NICE approves daclatasvir to treat adult HCV

Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23

NICE decision on ledipasvir/sofosbuvir for chronic HCV

Sofosbuvir/velpatasvir submitted to US FDA for HCV genotype 1-6

US indication for ledipasvir/sofosbuvir expanded

Protection against flu but not HBV in vaccinated perinatally HIV-infected children

Gilead to provide free hepatitis drugs to treat all people liviing with hepatitis C in Iceland

Australian doctors advice for buying generic sofosbuvir for HepC

Comprehensive review of DAA research at EASL

New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals

Sofosbuvir access: new patent challenges to sofosbuvir

Summary of the pre-conference clinical course

Hepatitis C drug access: Europe is the new Africa

India rejects Gilead’s patent application for sofosbuvir

Hepatitis C combination from AbbVie licensed in the UK: ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir (Exviera)

US activists called on Gilead to set a per-treatment price for sofosbuvir/ledipasvir

Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV



Daclatasvir approved in EU for HCV genotypes 1-4

CHMP gives positive opinion to approve coformulated sofosbuvir/ledipasvir

European activists protest at meeting of European Health Ministers for access to new HCV drugs

US Senate investigate Gilead for sofosbuvir price: potential to bankrupt Federal healthcare and add $300 annually to every American insurance premium for the next five years

Hepatitis C pipeline: BONANZA! The gold rush is under way

Global update: hepatitis C treatment activism

WHO launch treatment guidelines for hepatitis C (2014)

Sexually transmitted HCV in HIV positive and negative gay men

Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV

EMA fast-track sofosbuvir/ledipasvir FDC for hepatitis C

Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

New treatments for HCV: strategies for achieving universal access

EASL update guidelines for treatment of hepatitis C (2013)

Sofosbuvir approved in the US and Europe for HCV genotypes 1-6

Simeprevir approved in the US

Fair Pricing Coalition criticises cost of new HCV drugs

Boehringer Ingelheim stops development of deleobuvir for HCV

EU recommends approval of sofosbuvir for HCV

Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment

CID supplement on HCV and injecting drug users: free online issue

Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes

Executive summary and research policy recommendations

Hepatitis C drug development catapults onward

Low- and middle-income countries defuse hepatitis C

Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir

HIV/HCV coinfection: early glimpses of an interferon-free future and EuroSIDA incidence data

Cure rates with pipeline HCV drugs: reports from AASLD

Hepatitis C coinfection studies

FDA approve boceprevir (Victrelis) for HCV

FDA approve telaprevir (Incivek) to treat hepatitis C

FDA supplemental information about using boceprevir and telaprevir

The hepatitis C treatment pipeline

First results from telaprevir in HIV/HCV coinfection

Hepatitis B drugs in development

Hepatitis C treatment pipeline

Route of HCV transmission in HIV-positive gay men is unlikely to be from semen

Post navigation